Pages that link to "Q44734491"
Jump to navigation
Jump to search
The following pages link to High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia (Q44734491):
Displaying 50 items.
- Risperidone versus olanzapine for schizophrenia (Q24246232) (← links)
- A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression (Q24607731) (← links)
- Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 (Q24626912) (← links)
- Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia (Q24632939) (← links)
- High-frequency oscillations and the neurobiology of schizophrenia (Q26829587) (← links)
- Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling (Q27023967) (← links)
- Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia (Q28240120) (← links)
- Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia (Q28248687) (← links)
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia (Q28263502) (← links)
- Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia (Q28275290) (← links)
- Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy (Q30355399) (← links)
- Central nervous system uptake of intranasal glutathione in Parkinson's disease (Q33917288) (← links)
- Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia (Q33966168) (← links)
- Genetic Animal Models of Schizophrenia Related with the Hypothesis of Abnormal Neurodevelopment (Q34212280) (← links)
- Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission (Q34230984) (← links)
- Glutamatergic model psychoses: prediction error, learning, and inference (Q34661231) (← links)
- The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia (Q34970798) (← links)
- The therapeutic potential of glycine transporter-1 inhibitors (Q35779254) (← links)
- Glutamate as a therapeutic target in psychiatric disorders (Q35847653) (← links)
- N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives (Q36068372) (← links)
- Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment (Q36252816) (← links)
- Olanzapine: a critical review of recent literature (Q36273449) (← links)
- Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia (Q36302850) (← links)
- Augmentation of olanzapine in treatment-resistant schizophrenia (Q36331244) (← links)
- The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders (Q36712354) (← links)
- Protons Potentiate GluN1/GluN3A Currents by Attenuating Their Desensitisation. (Q36713681) (← links)
- Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions (Q36756365) (← links)
- Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia (Q36886717) (← links)
- High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors (Q37024727) (← links)
- Cycloid psychoses in the psychosis spectrum: evidence for biochemical differences with schizophrenia (Q37158915) (← links)
- Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study (Q37268726) (← links)
- Electrochemical studies for the determination of quetiapine fumarate and olanzapine antipsychotic drugs (Q37358793) (← links)
- ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression. (Q37583961) (← links)
- Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. (Q37621271) (← links)
- Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models (Q37794502) (← links)
- Pharmacotherapy for treatment-refractory schizophrenia (Q37831352) (← links)
- Pharmacological Strategies for Enhancing Cognition in Schizophrenia (Q37839921) (← links)
- Glutamate signaling in the pathophysiology and therapy of schizophrenia (Q37861323) (← links)
- Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications (Q38209092) (← links)
- Pharmacological treatment of negative symptoms in schizophrenia (Q38431333) (← links)
- Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials (Q38545655) (← links)
- Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. (Q38661176) (← links)
- Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators (Q39121207) (← links)
- Ultra-High-Field Magnetic Resonance Spectroscopy in Psychiatry (Q39458365) (← links)
- Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone (Q42931511) (← links)
- The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. (Q44153709) (← links)
- Three new olanzapine structures: the acetic acid monosolvate, and the propan-2-ol and propan-2-one hemisolvate monohydrates. (Q44585162) (← links)
- Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. (Q44850578) (← links)
- Modulation of striatal dopamine release by glycine transport inhibitors (Q45249011) (← links)
- Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma (Q46216712) (← links)